IL-6 is involved both in immune responses and in inflammation, hematopoiesis, bone
metabolism and embryonic development. IL-6 plays roles in chronic inflammation (closely …

In December 2019, a novel coronavirus was isolated from the respiratory epithelium of
patients with unexplained pneumonia in Wuhan, China. This pathogen, named severe acute …

The outbreak of coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2) infection, has emerged in China in December 2019 …

Background The efficacy of interleukin-6 receptor blockade in hospitalized patients with
coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic
with millions of human infections. One limitation to the evaluation of potential therapies and …

To date, seven identified coronaviruses (CoVs) have been found to infect humans; of these,
three highly pathogenic variants have emerged in the 21st century. The newest member of …

The disease course of COVID‐19 varies from asymptomatic infection to critical condition
leading to mortality. Identification of prognostic factors is important for prevention and early …

This systemic review and meta-analysis aimed to assess the efficacy of tocilizumab for the
treatment of severe coronavirus disease 2019 (COVID-19). Candidate studies up to 24 May …

The world is amid a pandemic caused by severe acute respiratory syndrome-coronavirus 2.
Severe acute respiratory syndrome-coronavirus causes serious respiratory tract infections …

Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of
severe COVID-19. The aim of this systematic review was to describe the rationale for the use …